A previously healthy 89-year-old female presented to the emergency room with four months of fevers and an unintentional 20-pound weight loss without noted lymphadenopathy. Prior to her hospitalization, the patient was evaluated at an outpatient clinic for high-grade fever and rash (Figure 1), which was treated as non-purulent cellulitis. Routine laboratory workup was unremarkable aside from AST 62 U/L (normal 10-65 U/L). After several courses of outpatient antibiotic therapies, two 5-day courses of Cephalexin, and a 10-day course of double-strength Trimethoprim-Sulfamethoxazole, the rash disappeared. However, her fevers and weight loss persisted, and she developed acute thrombocytopenia (platelets 31 K/uL (normal 150-400 K/uL)). During day six of her hospitalization, blood cultures became positive for Francisella tularensis, which was confirmed via RT-PCR and direct fluorescent antibody testing. Francisella tularensis antibody IgM was noted to be greater than 100 U/mL (9 or less is negative, 16 or greater positive), and IgG 80 U/mL (9 or less is negative, 16 or greater positive). Subsequent targeted history revealed the patient had sustained a tick bite while camping near the Western Canadian border before developing the initial rash with central eschar. Infectious disease was consulted, and the patient showed marked improvement in clinical symptoms with a prolonged course of intravenous antibiotics.
Eschar formation is characterized by an adherent brown-black crust with cutaneous necrosis that warrants diagnostic investigation. This is especially true in cases refractory or non-responsive to typical therapies, given the life-threatening nature of the possible underlying etiologies.1 A targeted history and physical exam should include infectious and non-infectious causes (Table 1).1–3 Between statewide reported cases from 2011 to 2019, the highest cases were recorded in Arkansas (374 cases, 20.4% total), followed by Missouri (13.1%), Oklahoma (11.9%), and Kansas (11.2%).4 In this specific case, the patient’s persistent fevers, despite appropriate antibiotics, raises concern for atypical infections, including necrotizing soft tissue infections, systemic bacterial infections, fungal infections, and zoonotic illnesses.
Tularemia is caused by the intracellular aerobic gram-negative bacteria Francisella tularensis, which can affect both humans and a diverse population of animals. Tularemia can be transmitted by animals to humans (commonly rodents and lagomorphs) as well as arthropod bites (tick and deer fly bites being most common in the United States).5 Additionally, Francisella tularensis can survive up to three months in water and six months in dry litter, and ingestion of contaminated foods and water sources or aerosolization of dry litter serves as opportunities for infection. Francisella tularensis is a category A bioterrorism agent; an infectious substance that, if exposure occurs, is capable of causing permanent disability, life-threatening, or fatal disease in otherwise healthy humans.6 Tularemia presents as an acute febrile illness and has many unique clinical manifestations that depend upon the mechanism of infection including ulceroglandular, glandular, oculoglandular, oropharyngeal, gastrointestinal, pneumonic, and typhoidal tularemia.7 The most common manifestation is ulceroglandular, which exhibits a characteristic skin lesion, as in our case. Diagnosing tularemia requires a high degree of suspicion. Screening for common risk factors, including animal interactions, ingestion of contaminated materials, or exposure to aerosolized litter in lawn mowing in endemic areas, may aid in identifying those to be tested. Tularemia diagnosis remains primarily based on history, clinical suspicion, and serological methods, but these tests are varied and poorly standardized.8 Most commonly, diagnosis is confirmed with either an initial titer > 1:160 or a four-fold rise between initial and convalescent serology.8 Francisella tularensis was incidentally found on blood culture and was confirmed with RT PCR and direct fluorescent antibody. Serologic studies should be performed only in patients in whom tularemia is a realistic possibility. Francisella tularensis is a β-lactamase producing bacteria, and the first line treatment consists of a 7–14-day course of either intravenous streptomycin or gentamicin. Fluoroquinolones and tetracyclines are alternative therapy options but are typically reserved for mild cases and may be associated with higher rates of relapse.5,7,9
Author Contributions
All authors have reviewed the final manuscript prior to submission. All the authors have contributed significantly to the manuscript, per the International Committee of Medical Journal Editors criteria of authorship.
-
Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
-
Drafting the work or revising it critically for important intellectual content; AND
-
Final approval of the version to be published; AND
-
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Disclosures/Conflicts of Interest
The authors report no financial conflicts of interest.
Corresponding author
Kang Zhang, MD
Department of Internal Medicine
Spokane Teaching Health Center Spokane, WA, USA
Email: kang.zhang@providence.org